Denali Capital Acquisition CorpDECA
DECA
About: Denali Capital Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
37.6% more ownership
Funds ownership: 61.69% [Q2] → 99.29% (+37.6%) [Q3]
59% less funds holding
Funds holding: 17 [Q2] → 7 (-10) [Q3]
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
76% less capital invested
Capital invested by funds: $34.7M [Q2] → $8.4M (-$26.3M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for DECA.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from December 11, 2024 to January 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $104,708.30 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.
Neutral
GlobeNewsWire
1 month ago
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $119,772.04 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.
Neutral
GlobeNewsWire
2 months ago
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from October 11, 2024, to November 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $134,835.78 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.
Positive
Reuters
3 months ago
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal
Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company , will go public via a merger with special purpose acquisition company Denali Capital Acquisition Corp in a $2.5 billion deal, the companies said on Tuesday.
Neutral
GlobeNewsWire
4 months ago
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from August 11, 2024, to September 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $164,963.26 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.
Neutral
GlobeNewsWire
5 months ago
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the “Articles”) to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the “Extension”).
Positive
Benzinga
5 months ago
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company SCLX, and Denali Capital Acquisition Corp. DECA, a special purpose acquisition company, signed a letter of intent for a proposed business combination.
Positive
Reuters
5 months ago
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-transaction equity deal valued at up to $2 billion.
Neutral
GlobeNewsWire
6 months ago
Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.
Neutral
GlobeNewsWire
6 months ago
Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.
Charts implemented using Lightweight Charts™